Back to search

Article

Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

2025-09-04

Abstract excerpt

Myasthenia gravis (MG), a well understood antibody-mediated autoimmune disease, is characterized by skeletal muscle weakness and fatigue. The autoantibodies are directed against neuromuscular junction (NMJ) proteins such as the acetylcholine receptor (AChR), essential for neuromuscular signal transmission. Anti-AChR antibodies are mainly of the immunoglobulin (Ig) types IgG1 and IgG3, which have a high capacity to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f3658380-cff7-56d8-adb9-d274e5645170
DOI
10.1101/2025.08.31.673367
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)DOI 10.1101/2025.08.31.673367
The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?Semantic proximity
Complement and myasthenia gravisSemantic proximity
Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.Semantic proximity
Pathogenesis of myasthenia gravis: update on disease types, models, and mechanismsSemantic proximity
Dilemma on Animal Models for Ocular Myasthenia Gravis: Can Lipoprotein Receptor-related Protein 4 Experimental Autoimmune Myasthenia Gravis Fix This Problem?Semantic proximity
Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificitiesSemantic proximity
Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.Semantic proximity
Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravisSemantic proximity
Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.Semantic proximity
Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity
Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies.Semantic proximity
Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravisSemantic proximity
Select a neighboring publication to make it the new centre.